We have observed
15 EP applications
James Michael Frederic Horgan
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 16, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS
BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS
THERAPEUTIC ANTI-IGF1R COMBINATIONS
USE OF MDL-1 ANTAGONISTS TO TREAT SPONDYLARTHROPATHY
AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES
AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS
AMINOPYRIMIDINES AS SYK INHIBITORS
PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS
STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENTS
METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES
DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH
QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS
ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1